Opendata, web and dolomites

StopAddict SIGNED

The game changer drug to cure alcohol use disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StopAddict project word cloud

Explore the words cloud of the StopAddict project. It provides you a very rough idea of what is the project "StopAddict" about.

companies    save    expenses    neuropsychopharmacology    treatments    implicated    licensing    situation    first    smei2    updated    leader    addiction    damaging    2027    people    117m    2018    seeking    lives    intensive    triple    unsuccessful    mechanism    deals    2009    400    mise    therapeutics    disease    drug    revenues    2025    70    cumulative    disorders    fto    characterised    action    award    burden    huge    10    discovered    actions    alcoholism    283    agency    create    efficacy    aud    social    poor    alcohol    achievement    direct    patient    stopaddict    110    adjusted    billion    college    commercialisation    million    man    consumption    generating    french    worldwide    life    therapies    continuous    context    communities    kt    clinical    trial    newly    treatment    dead    disability    pharma    decreasing    uncontrolled    granted    132    leads    recovery    jobs    suffer    ip    accepted    persons    kinnov    successful    patients    indirect    families    society    class    regulatory    revolutionary   

Project "StopAddict" data sheet

The following table provides information about the project.

Coordinator
KINNOV THERAPEUTICS 

Organization address
address: 3 ALLEE DU TITANE
city: Orleans
postcode: 45100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙432˙400 €
 EC max contribution 2˙402˙680 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KINNOV THERAPEUTICS FR (Orleans) coordinator 2˙402˙680.00

Map

 Project objective

Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment. In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009. After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2. Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPADDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOPADDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

APS (2019)

On-site and On-demand Flexible Packaging System

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More